Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Filgotinib · GS-6034, GLPG0634

Small molecule · Inhibitor of JAK1 · developed by GILEAD SCIENCES

Phase 3 Most advanced trial (none active)

GILD Developer

1 Registered trials

What is Filgotinib?

Filgotinib is an orally bioavailable small-molecule inhibitor of JAK1 tyrosine kinase. It inhibits JAK1 phosphorylation to block JAK/STAT-dependent signaling and reduce pro-inflammatory cytokine activity. It is studied in ulcerative colitis and other inflammatory and autoimmune diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: GS-6034, GLPG0634, G-146034
Drug type: Small molecule
Targets: JAK1
Mechanism: Inhibitor of JAK1
Pathways: JAK/STAT signaling, cytokine signaling
Therapy area: Gastroenterology
Developer: GILEAD SCIENCES (GILD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 3XVL385Q0M

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02914535	Phase 3	Ulcerative Colitis	Completed	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

Other drugs acting on JAK1

Baricitinib FDA approved Upadacitinib FDA approved

More from GILEAD SCIENCES

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Filgotinib

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z